Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 5670K) PPT slides of all figures Supplemental Material Index Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Clark, R. A. Articles by Kupper, T. S. Search for Related Content PubMed PubMed Citation Articles by Clark, R. A. Articles by Kupper, T. S. Related Collections Related In this Issue article Social Bookmarking                            What's this?

¹ Harvard Skin Disease Research Center and the Department of Dermatology, and ² Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115
³ Department of Dermatology, Ghent University Hospital, B-9000 Ghent, Belgium
⁴ Department of Dermatology, Utrecht University Medical Center, 3508 GA Utrecht, Netherlands
⁵ University of Maryland, Program in Molecular and Cell Biology, College Park, MD 20742

CORRESPONDENCE Rachael A. Clark: rclark1{at}partners.org

Squamous cell carcinomas (SCCs) of the skin are sun-induced skin cancers that are particularly numerous in patients on T cell immunosuppression. We found that blood vessels in SCCs did not express E-selectin, and tumors contained few cutaneous lymphocyte antigen (CLA)⁺ T cells, the cell type thought to provide cutaneous immunosurveillance. Tumors treated with the Toll-like receptor (TLR)7 agonist imiquimod before excision showed induction of E-selectin on tumor vessels, recruitment of CLA⁺ CD8⁺ T cells, and histological evidence of tumor regression. SCCs treated in vitro with imiquimod also expressed vascular E-selectin. Approximately 50% of the T cells infiltrating untreated SCCs were FOXP3⁺ regulatory T (T reg) cells. Imiquimod-treated tumors contained a decreased percentage of T reg cells, and these cells produced less FOXP3, interleukin (IL)-10, and transforming growth factor (TGF)-β. Treatment of T reg cells in vitro with imiquimod inhibited their suppressive activity and reduced FOXP3, CD39, CD73, IL-10, and TGF-β by indirect mechanisms. In vivo and in vitro treatment with imiquimod also induced IL-6 production by effector T cells. In summary, we find that SCCs evade the immune response at least in part by down-regulating vascular E-selectin and recruiting T reg cells. TLR7 agonists neutralized both of these strategies, supporting their use in SCCs and other tumors with similar immune defects.

© 2008 Clark et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related In this Issue article

Tumor-fighting T cells lose their way

Rebecca Blank
J. Exp. Med. 2008 205: 2182. [Full Text] [PDF]

This article has been cited by other articles:

• Terabe, M., Ambrosino, E., Takaku, S., O'Konek, J. J., Venzon, D., Lonning, S., McPherson, J. M., Berzofsky, J. A. (2009). Synergistic Enhancement of CD8+ T Cell-Mediated Tumor Vaccine Efficacy by an Anti-Transforming Growth Factor-{beta} Monoclonal Antibody. Clin. Cancer Res. 15: 6560-6569 [Abstract] [Full Text]  
• Zhou, Q., Bucher, C., Munger, M. E., Highfill, S. L., Tolar, J., Munn, D. H., Levine, B. L., Riddle, M., June, C. H., Vallera, D. A., Weigel, B. J., Blazar, B. R. (2009). Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood 114: 3793-3802 [Abstract] [Full Text]  
• Chen, H., Liakou, C. I., Kamat, A., Pettaway, C., Ward, J. F., Tang, D. N., Sun, J., Jungbluth, A. A., Troncoso, P., Logothetis, C., Sharma, P. (2009). Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-{gamma} levels in both nonmalignant and malignant prostate tissues. Proc. Natl. Acad. Sci. USA 106: 2729-2734 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS